Clinical Trial Update: Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update proposes reducing elective nodal and clinical target volume doses for HPV-positive oropharyngeal squamous cell carcinoma; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-positive Oropharyngeal Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Snippet

Sponsor: Sara Medek | Conditions: Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING